Overview

A Study Evaluating Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Cancer

Status:
Terminated
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out the effects, good and/or bad, of the combination of two drugs, gemcitabine and bosutinib, in patients with resected pancreatic cancer and whether this combination can prevent pancreatic cancer from coming back.
Phase:
Phase 1
Details
Lead Sponsor:
University of California, San Francisco
Collaborator:
University of Utah
Treatments:
Gemcitabine